pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Epic's data‑blocking tactics curb health‑tech innovation, investigation finds

Oct 28, 2026·read at STAT ↗Negative

A STAT investigation reveals that Epic Systems, the leading electronic health record vendor, is deliberately limiting access to patient data for competing software developers. This practice gives Epic disproportionate control over which applications can thrive in U.S. hospitals.

The report says Epic’s selective withholding of data disadvantages rivals, effectively deciding which tools succeed or fail. By restricting data flow, the company stifles the development of new health‑technology solutions that could benefit providers and patients.

Researchers interviewed more than 50 sources, including former Epic staff, app developers, and hospital executives, to document these tactics. The investigation places Epic’s behavior in the context of a broader AI boom in healthcare, where data access is crucial for innovation.

Industry observers warn that Epic’s grip on patient information could slow the rollout of advanced analytics and AI tools, limiting options for hospitals and potentially hindering improvements in care delivery.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology”

read at STAT ↗
761 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Disc Medicine, Inc.2Day One Biopharmaceuticals, Inc.LEADINGRISING
drugs
iron2
topics
ApprovalCell TherapyGene Therapy (AAV)Immunology

related stories

  • Dec 22Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series AFierce Biotech
  • 20h agoTeva closing New Jersey manufacturing facility, laying off 61 employeesBioSpace
  • Oct 5Swiss CDMOs and CROs ride a new wave of growth amid surge in global demandBioSpace
  • Oct 1Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOFierce Biotech
  • Sep 4Ionis’ rare neurology drug approved; Pfizer inks an ADC dealBioPharma Dive